ArticleCancer research communications2026
OB-001 Enhances Osimertinib Brain Penetration: Preclinical Pharmacokinetics and Translational Rationale for EGFR-Mutant NSCLC with CNS Disease.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with proven efficacy in EGFR-mutant non-small cell lung cancer (NSCLC), including patients with central nervous system (CNS) disease. However, pharmacokinetic (PK) studies demonstrate low CNS penetration (CSF:plasma 0.8%-22%), largely due to ABCB1/ABCG2 efflux. OB-001, a KinetiSol amorphous solid dispersion formulation of elacridar, was developed to overcome the poor bioavailability of crystalline elacridar and evaluated as a strategy to enhance osimertinib brain delivery. In CD-1 mice, we compared the oral bioavailability of OB-001 (10, 30, 100 mg/kg) with crystalline elacridar (100 mg/kg) and assessed osimertinib (50 mg/kg orally) brain distribution after pretreatment with OB-001 (10 or 50 mg/kg) or crystalline elacridar (100 mg/kg). Plasma and perfused brain PK parameters were derived by noncompartmental analysis. AUClast values were compared using Bailer randomization test. OB-001 achieved greater systemic elacridar exposure than the crystalline methylcellulose suspension (P < 0.001). In vehicle-pretreated mice, osimertinib produced a brain:plasma AUC ratio of 7.1. OB-001 pretreatment increased brain AUClast 4-fold (10 mg/kg; P < 0.001) and 9.3-fold (50 mg/kg; P < 0.001) with minimal plasma change (1.1-1.4-fold). Crystalline elacridar at 100 mg/kg increased brain AUClast 5-fold (P < 0.001). Thus, OB-001 at 10 mg/kg achieved comparable brain enhancement with 10-fold higher dose of crystalline elacridar, whereas OB-001 at 50 mg/kg exceeded it. Translational benchmarking against in vitro potency suggested that raising estimated Kp,uu from ∼0.15 to ∼0.60 could improve efficacy. OB-001 selectively boosts osimertinib brain exposure while sparing systemic PK. These preclinical data support further evaluation of OB-001 as a strategy to enhance the CNS efficacy of osimertinib in EGFR-mutant NSCLC. SIGNIFICANCE: Blood-brain barrier (BBB) efflux limits osimertinib brain exposure. Oral OB-001 pretreatment markedly increases brain concentrations with minimal plasma impact, supporting BBB transporter inhibition as a strategy to enhance CNS drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.